Campath-1H [alemtuzumab] induction to allow steroid free immunosuppression in pediatric renal transplantation

Trial Profile

Campath-1H [alemtuzumab] induction to allow steroid free immunosuppression in pediatric renal transplantation

Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 15 Oct 2015

At a glance

  • Drugs Alemtuzumab (Primary)
  • Indications Renal transplant rejection
  • Focus Therapeutic Use
  • Most Recent Events

    • 09 Oct 2015 Status changed from suspended to discontinued, as reported by ClinicalTrials.gov.
    • 09 Dec 2013 Planned end date changed from 1 May 2014 to 1 Dec 2014 as reported by ClinicalTrials.gov.
    • 25 Jun 2012 Planned number of patients changed from 35 to 50 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top